General Information

We are a medical technology company specializing in predictive analytic, early stage lung cancer risk testing, which we refer to as the “ProLung Test.” Our noninvasive, painless and radiation-free ProLung Test was developed to immediately assess the risk of malignancy in lung nodules found in the chest by a Computed Tomography (“CT”) scan, which is currently the primary method used for the early detection of lung cancer. As lung cancer is the leading cause of cancer death, early detection makes a substantial improvement in survival in a large population group. Timely identification of malignancy is essential for patients and their families. Currently, patients wait from three months to three and one-half years to have the risk of malignancy assessed through periodic CT scan surveillance. Until malignancy is determined to be likely, invasive biopsy and treatment are significantly delayed. Current statistics reflect a 17% survival rate at five years for those diagnosed with lung cancer.

Employees: 15
Founded: 2004
Contact Information
Address 757 East South Temple, Suite 150, Salt Lake City, UT 84102, US
Phone Number (801) 736-0729
Web Address
View Prospectus: ProLung
Financial Information
Market Cap $36.0mil
Revenues $0 mil (last 12 months)
Net Income $-4.3 mil (last 12 months)
IPO Profile
Symbol LUNG
Exchange NASDAQ
Shares (millions): 0.9
Price range $7.00 - $8.00
Est. $ Volume $7.0 mil
Manager / Joint Managers Maxim Group/ Aegis Capital
CO-Managers -
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change